Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Among myeloma pt adherence groups getting IMiDs (1-persistently-high-33.1%, 2-quick-decline-then-increase-17.5%, 3-moderate-decline-21.2%, 4-quick-decline-28.2%), poor-adherence groups had a >20% increased mortality risk.”
Title: Immunomodulatory Agent Adherence Trajectories and Survival Among Older Patients With Multiple Myeloma
Authors: Rong Wang, Mengmeng Ji, Natalia Neparidze, Xiaomei Ma, Su-Hsin Chang, Shi-Yi Wang
You can read the Full Article in JCO Oncology Practice.
You can find other articles featuring Robert Orlowski on OncoDaily.
